Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Receivables (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Change in Receivables for 6 consecutive years, with $13.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 2104.78% to $13.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.2 million, a 599.44% increase, with the full-year FY2025 number at $36.2 million, up 599.44% from a year prior.
  • Change in Receivables was $13.4 million for Q4 2025 at GeneDx Holdings, up from $12.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $13.4 million in Q4 2025 to a low of -$13.5 million in Q2 2022.
  • A 5-year average of $991150.0 and a median of -$243500.0 in 2022 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 2359.42% in 2024; the steepest drop was 435.0% in 2024.
  • GeneDx Holdings' Change in Receivables stood at $5.3 million in 2021, then plummeted by 100.69% to -$36000.0 in 2022, then skyrocketed by 655.56% to $200000.0 in 2023, then crashed by 435.0% to -$670000.0 in 2024, then skyrocketed by 2104.78% to $13.4 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Change in Receivables are $13.4 million (Q4 2025), $12.9 million (Q3 2025), and $1.3 million (Q2 2025).